US2014371241A1PendingUtilityA1

Tec family kinase inhibitor adjuvant therapy

59
Assignee: PHARMACYCLICS INCPriority: Nov 2, 2012Filed: Mar 5, 2014Published: Dec 18, 2014
Est. expiryNov 2, 2032(~6.3 yrs left)· nominal 20-yr term from priority
Inventors:Joseph J. BuggyTarak D. ModyRichard B. LoveJohn C. ByrdBetty Y. ChangJason A. DubovskyNatarajan MuthusamyAmy J. Johnson
A61P 37/02A61P 37/00A61P 43/00A61P 35/00A61P 31/00A61P 29/00A61P 35/02A61K 31/519A61K 45/06
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

Claims

exact text as granted — not AI-modified
1 .- 33 . (canceled) 
     
     
         34 . A method for treating a patient having a relapsed or refractory chronic lymphocytic leukemia, comprising administering to the patient a Btk inhibitor and a Bcl-2 inhibitor. 
     
     
         35 . The method of  claim 34  wherein the Btk inhibitor is ibrutinib. 
     
     
         36 . The method of  claim 35  wherein ibrutinib is administered at a dosage of about 40 mg/day to about 1000 mg/day. 
     
     
         37 . The method of  claim 34  wherein the patient has deletion in 17p. 
     
     
         38 . The method of  claim 37  wherein the deletion in 17p is assessed by a biomarker screen.

Join the waitlist — get patent alerts

Track US2014371241A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.